How it works
How Much Does Ocrevus (ocrelizumab) Cost in Spain?
Ocrevus (ocrelizumab) in Spain typically costs from $11,700 to $22,000 per year for private patients. Pricing depends on the specific clinic tier, city, and required pre-infusion diagnostic tests. In the US, similar treatments cost around $45,000 on average. Patients save around 62% compared to US list prices. Private costs in Spain usually include the medication, nursing care, and initial blood screenings.
- Private infusion sessions: $11,700 to $22,000 per cycle including clinical monitoring.
- Major medical hubs: Primary treatment centers are located in Madrid and Barcelona.
- Clinic tier variations: Costs at Joint Commission International (JCI) accredited facilities reflect premium specialized care.
- Ancillary services: Pricing often factors in mandatory Hepatitis B screenings and post-infusion observation.
Bookimed Expert Insight: Choosing a research-heavy center like Hospital Universitario HM Madrid or Centro Médico Teknon offers significant value. These clinics are led by experts like Dr. Rafael Arroyo González, who has led over 100 clinical trials. Patients benefit from JCI-accredited safety standards and extensive neurological expertise. Facilities in Barcelona and Madrid provide comparable pricing while maintaining some of the highest patient volumes in Europe.
| Turkey | Austria | Spain | |
|---|---|---|---|
| Ocrevus (ocrelizumab) | ≈ $4,500 | ≈ $8,800 | from $11,700 |
Discover the Best Ocrevus (ocrelizumab) Clinics in Spain: 4 Verified Options and Prices
HOSPITAL UNIVERSITARIO HM MADRID
José Angel Obeso






Hospital HM Nou Delfos
Rodrigo Rocamora




Ocrevus (ocrelizumab) Overview in Spain
- Ocrevus (ocrelizumab) - from $11,700This therapy is a vital medication for multiple sclerosis, reducing relapse rates and slowing disease progression.
Day 1: Arrival
- Arrive at the hospital for your appointment.
- Complete the necessary paperwork and medical history forms.
- Consult with your doctor about the Ocrevus (ocrelizumab) treatment.
Day 2: Pre-Operation
- Undergo a complete physical examination.
- Complete necessary blood tests and MRI if instructed by your doctor.
- Meet with a neurologist for a thorough evaluation.
Day 3: Ocrevus (ocrelizumab) Infusion
- Arrive at the clinic for your scheduled infusion.
- Receive pre-medication to reduce the risk of infusion-related reactions.
- Undergo Ocrevus (ocrelizumab) infusion which lasts about 4 hours.
- Stay in the clinic for observation for at least an hour post-infusion.
Week 1-2: Post-Operation
- Monitor your health for any side effects or reactions.
- Report any unusual symptoms to your doctor immediately.
- Schedule a follow-up appointment with your doctor.
Week 3-4: Rehabilitation
- Continue daily activities as tolerated, avoiding strenuous exertion initially.
- Gradually return to work and other activities as your body allows.
Please note that each patient"s experience with Ocrevus (ocrelizumab) can differ. Always consult with your healthcare team for personalized advice.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Anna Pujol
Dr. Anna Pujol is a neurologist at Teknon Medical Center in Barcelona. She specialize in chronic headaches, migraines, and neuromuscular diseases. Dr. Pujol previously served as the Memory Research Unit coordinator at Sant Pau Hospital. She holds a PhD focused on neurological complications of liver transplantation.
- Member of the American Academy of Neurology and the Catalan Society of Neurology.
- Treats memory disorders, multiple sclerosis, and neurological complications of COVID-19.
- Served as a Professor of Neurology at the Higher Institute of Psychological Studies.
- Works at Teknon, a JCI-accredited hospital and Newsweek-ranked facility.

Jesus Romero Imbroda
Dr Romero Imbroda leads the Neurology Unit at Quirónsalud Marbella, specializing in multiple sclerosis treatments like Ocrevus. His research includes cutting-edge therapies for MS.
- President of the Andalusian Society of Neurology
- Fellow of the European Board of Neurology
- Lecturer at the University of Granada
- Author of national and international scientific publications
- Head of Neurology Units at Quirónsalud Malaga and Marbella

Rafael Arroyo González
Principal investigator in 100+ clinical trials for neurological treatments, including Ocrevus studies. Dr. Arroyo leads Quironsalud Madrid's Neurology Department.
- Head of Neurology since 2006 at Quironsalud University Hospital
- Published 139 international articles in top journals like New England Journal of Medicine
- Professor of Medicine with national accreditation
- Specializes in multiple sclerosis research and treatment

José Angel Obeso
A pioneer in movement disorders with 50 years of experience, Dr. Obeso leads the HM CINAC Integral Neurosciences Centre in Madrid.
- Developed Continuous Dopaminergic Stimulation for Parkinson's
- Published 350+ research articles on neurology
- Member of the American Neurological Association
- Founder of the Movement Disorders Group in Spain
Reviews about Bookimed: Discover Patients' Insights
All reviews





Share this content
Video Stories from Bookimed Patients
Anna Leonova
FAQ about Ocrevus (ocrelizumab) in Spain
What safety checks are required before Ocrevus infusions?
Prior to Ocrevus infusions, patients must undergo Hepatitis B screening, a vaccination status review, and a pregnancy check. Physicians confirm the absence of active infections and administer mandatory pre-medications, including corticosteroids and antihistamines, to prevent infusion-related reactions. In Spain, JCI-accredited hospitals provide these specialized neuro-immunology services.
- Viral screening: Providers conduct blood tests for Hepatitis B to prevent potentially fatal viral reactivation.
- Vaccination timing: All live vaccines must be administered at least 4 weeks before starting treatment.
- Pre-medication protocol: Patients receive anti-pyretics and steroids 30 to 60 minutes before the intravenous infusion.
- Vital monitoring: Medical staff monitor blood pressure and heart rate every 15 to 30 minutes.
Bookimed Expert Insight: While standard Ocrevus infusions take 3.5 hours, high-volume Spanish centers like Hospital HM Nou Delfos offer FAST infusions lasting only 2 hours. This protocol is typically reserved for subsequent doses if the patient showed no reactions during the initial 6-month cycle. Choosing clinics with 75,000+ annual patients ensures the nursing team is highly experienced in managing these specific titration speeds safely.
Patient Consensus: Patients emphasize arriving in comfortable clothing and arranging a driver, as pre-infusion antihistamines often cause significant drowsiness. Many recommend avoiding unmasked crowds for 2 months post-infusion to manage the period of peak immune suppression.
What are the side effects of Ocrevus?
Ocrevus most commonly causes infusion-related reactions such as itchy skin, rash, and throat irritation within 24 hours. Because it suppresses B-cells, patients face a higher risk of upper respiratory infections. Serious risks include progressive multifocal leukoencephalopathy (PML) and potential malignancies like breast cancer.
- Infusion reactions: Most common during first half-dose; causing flushing, itching, or throat swelling.
- Infection risk: Lowers immune response, increasing susceptibility to colds, bronchitis, and herpes outbreaks.
- Neurological safety: Rare risk of PML, a serious brain infection requiring immediate monitoring.
- Pre-medication effects: Steroids often cause temporary mood volatility, anxiety, insomnia, or intense fatigue.
Bookimed Expert Insight: While clinical data focuses on drug side effects, our records show secondary symptoms often stem from pre-medications. At clinics like Hospital Ruber Internacional or Teknon Medical Center, neurologists use high-dose Benadryl and steroids to prevent allergies. Patients frequently mistake the resulting dizziness or `jelly legs` for the Ocrevus itself.
Patient Consensus: Many report feeling cold during infusions due to IV fluids and suggest bringing blankets. Recovery typically involves 1–2 days of extreme fatigue or migraines before side effects subside.
How long does it take for Ocrevus to work?
Ocrevus begins reducing disability progression within 12 weeks of your first infusion. While initial immune system changes occur shortly after treatment, most patients require at least 6 months to observe significant effects in preventing new brain lesions and halting disease activity.
- Initial treatment phase: Patients receive two infusions spaced 14 days apart to start therapy.
- Clinical efficacy window: Significant brain lesion reduction usually appears between 12 and 24 weeks.
- Long-term disease management: Major disability progression slowing is typically measured over a 96-week period.
- Preventive therapy role: This medication prevents new damage rather than healing existing neurological injuries.
Bookimed Expert Insight: Spain ranks 4th globally for MS treatments on our platform due to high-volume specialist centers. Leading neurologists like Dr. Rafael Arroyo González at Quironsalud Madrid oversee over 100 clinical trials. This high research volume ensures patients receive the most advanced dosing protocols available.
Patient Consensus: Patients emphasize that Ocrevus acts like birth control for MS to prevent new damage. Most recommend taking 2 days off work for each session to manage steroid-induced fatigue.
How is Ocrevus administered in Spain?
Ocrevus (ocrelizumab) in Spain is administered as an intravenous infusion in specialized hospital settings. Treatment follows a strict six-month maintenance cycle under the supervision of specialists at JCI-accredited centers in Madrid and Barcelona. Home administration is not currently permitted within the Spanish medical protocol.
- Dosage schedule: Initial doses are split two weeks apart, followed by 600 mg every 6 months.
- Infusion duration: Sessions last 4–5 hours, though experienced patients may reduce this to 2 hours.
- Mandatory monitoring: Medical teams observe patients for at least 1 hour post-infusion for potential reactions.
- Pre-medication protocol: Specialists often provide steroids or antihistamines 30–60 minutes before starting the IV.
Bookimed Expert Insight: While standard infusions take up to 5 hours, experienced patients at top centers like Hospital Universitario HM Madrid can significantly shorten their visit. By opting out of optional pre-medications after successful prior sessions, you can reduce the clinical stay to approximately 2 hours without compromising safety.
Patient Consensus: Patients emphasize planning for a full hospital day and confirm that self-administration is not an option. Many appreciate the streamlined outpatient process where they can walk out immediately after the observation period ends.
Where are the main treatment centers for Ocrevus located in Spain?
Main treatment centers for Ocrevus in Spain are concentrated in Madrid and Barcelona at JCI-accredited facilities like Hospital Ruber Internacional and Centro Médico Teknon. These hubs utilize experienced neurologists and specialized neurosciences centers to manage multiple sclerosis through intravenous monoclonal antibody infusion therapy.
- Madrid facilities: Hospital Ruber Internacional and Hospital Universitario HM Madrid lead neurological care in the capital.
- Barcelona centers: Centro Médico Teknon and Hospital HM Nou Delfos provide advanced multiple sclerosis treatments.
- Specialized experts: Dr. Rafael Arroyo González in Madrid leads extensive clinical trials for multiple sclerosis.
- Quality standards: Top centers maintain JCI and ISO certifications ensuring high patient safety and reliability.
Bookimed Expert Insight: While many patients focus on Madrid or Barcelona, Quirónsalud Marbella offers specialized care under Dr. Jesus Romero Imbroda. As President of the Andalusian Society of Neurology, his expertise provides a high-tier alternative outside the major metropolitan hubs. This is particularly valuable for international patients seeking care in coastal regions without compromising on clinical leadership.
Patient Consensus: Patients emphasize the importance of bringing complete medical records from home to ensure a smooth transition of care. Legal residents typically access treatment through the public system, though private facilities remain the primary choice for international visitors.










